ArticleCellular and molecular neurobiology2011
Effect of cavtratin, a caveolin-1 scaffolding domain peptide, on oligodendroglial signaling cascades.
Article in Cellular and molecular neurobiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Physiological and pathological roles of caveolins in the central nervous system.Trends in neurosciences · 2024Review
- Glucocorticoid-mediated induction of caveolin-1 disrupts cytoskeletal organization, inhibits cell migration and re-epithelialization of non-healing wounds.Communications biology · 2021Article
- Multifaceted Roles of Caveolin-1 in Lung Cancer: A New Investigation Focused on Tumor Occurrence, Development and Therapy.Cancers · 2020Review
- Caveolin-1 Scaffolding Domain Peptide Regulates Colon Endothelial Cell Survival through JNK Pathway.International journal of inflammation · 2020Article
- Deletion of caveolin scaffolding domain alters cancer cell migration.Cell cycle (Georgetown, Tex.) · 2019Article
- Inhibitory effect of caveolin-1 in vascular endothelial cells, pericytes and smooth muscle cells.Oncotarget · 2017Article
- Caveolin-1 Protects Retinal Ganglion Cells against Acute Ocular Hypertension Injury via Modulating Microglial Phenotypes and Distribution and Activating AKT pathway.Scientific reports · 2017Article
- Contemporary Approaches to Modulating the Nitric Oxide-cGMP Pathway in Cardiovascular Disease.Circulation research · 2017Review
- Caveolin proteins: a molecular insight into disease.Frontiers of medicine · 2016Review
- Role of nitric oxide in murine conventional outflow physiology.American journal of physiology. Cell physiology · 2015Article
- Caveolin-1 is a negative regulator of tumor growth in glioblastoma and modulates chemosensitivity to temozolomide.Cell cycle (Georgetown, Tex.) · 2013Article
- Caveolin-1 as a promoter of tumour spreading: when, how, where and why.Journal of cellular and molecular medicine · 2013Review
- Oligodendroglial process formation is differentially affected by modulating the intra- and extracellular cholesterol content.Journal of molecular neuroscience : MN · 2013Article
- Caveolin-1, caveolae, and glioblastoma.Neuro-oncology · 2012Review
- Anti-caveolin-1 antibodies as anti-prostate cancer therapeutics.Hybridoma (2005) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Caveolin and caveolin containing rafts are involved in the signaling of growth factors in various cell types. Previous reports of our lab indicated a co-localization of caveolin and the high affinity nerve growth factor (NGF) receptor tyrosine kinase A (TrkA). Mutual effects have been observed among which a caveolin-1 knock-down resulted in an impairment of the NGF signaling cascade rather than in an increase of activity as expected from other growth factor reports. On the other hand, an over-expression of caveolin-1 impaired the NGF stimulated activity of p42/44 mitogen activated protein kinases (MAPK). In this study, we used a caveolin-1 scaffolding domain (CSD) peptide (cavtratin) of which an inhibitory effect on growth factor receptors was reported. Our data showed that cavtratin suppresses the NGF-induced phosphorylation of TrkA as well as the activation of MAPK in porcine oligodendrocytes significantly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.